CeraVe Diabetes Mellitus

• Status: Recruiting
• Trial end date: 2022-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of the CeraVe Diabetic Skin Line for the improvement of skin condition in patients with diabetes mellitus.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Miami
• Collaborator: CeraVe
• Treatments: Dimenhydrinate

Criteria

Inclusion Criteria:

1. Men or women between the ages of 18 and 75 years of age.

2. Willing to provide written informed consent.

3. A diagnosis of diabetes mellitus (DM).

4. DM-related skin changes classified into one or more of the following four categories:

i) skin lesions associated with DM; ii) infections; iii) cutaneous manifestations of DM complications; iv) skin reaction to DM treatment.

Exclusion Criteria:

1. History of allergy, anaphylaxis or hypersensitivity to any of the ingredients in CeraVe Hydrating Cleanser or Moisturizing Cream

2. History of allergic contact dermatitis secondary to cleansers or moisturizers.

3. Has a heightened immune response to common allergens, especially inhaled, topical or food allergens (atopy).

4. Has any clinical manifestation in the treatment are(s) or other disorders that, in the investigator's opinion, may affect assessments or the study products.

5. Inability to attend all study visits and follow treatment regimen.